Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
BACKGROUND
The use of imiquimod 5% cream for the treatment of superficial basal cell carcinoma (BCC) has been described. Its clinical efficacy was first shown in a study in patients with biopsy-proven superficial and nodular BCC.


OBJECTIVE
To evaluate the efficacy of topical imiquimod in a patient with multiple superficial BCCs unresponsive to topical 5-fluorouracil and to review the literature on this treatment modality for BCCs.


RESULTS
After 12 weeks of topical imiqmod, the patient's lesions had resolved. The patient was evaluated three months after discontinuation of treatment. There was no clinical evidence of any recurrent tumor.


CONCLUSIONS
Imiquimod 5% cream appears to be effective for multiple, superficial BCCs unresponsive to other modalities.
Drehs
Molly M
MM
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.
Cook-Bolden
Fran
F
Tanzi
Elizabeth L
EL
Weinberg
Jeffrey M
JM
D000287:Administration, Topical; D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod